NMC
PHAS

NEA Management Company’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

NEA Management Company’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,643,702
Closed -$1.17M – 61
2022
Q3 		$1.17M Hold
6,643,702
– – 0.06% 52
2022
Q2 		$3.99M Hold
6,643,702
– – 0.2% 48
2022
Q1 		$8.77M Sell
6,643,702
-2
-0% -$3 0.25% 44
2021
Q4 		$17.3M Hold
6,643,704
– – 0.35% 35
2021
Q3 		$20.7M Hold
6,643,704
– – 0.25% 36
2021
Q2 		$24.7M Hold
6,643,704
– – 0.32% 37
2021
Q1 		$23M Hold
6,643,704
– – 0.52% 37
2020
Q4 		$22.3M Hold
6,643,704
– – 0.59% 34
2020
Q3 		$23.3M Hold
6,643,704
– – 0.99% 29
2020
Q2 		$30.6M Hold
6,643,704
– – 1.23% 21
2020
Q1 		$22M Hold
6,643,704
– – 1.15% 19
2019
Q4 		$40.6M Hold
6,643,704
– – 1.92% 16
2019
Q3 		$27.7M Hold
6,643,704
– – 2.29% 12
2019
Q2 		$87.2M Buy
+6,643,704
New +$81.4M 6.11% 6

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

NEA Management Company's PHAS Position: Q4 2022 in Review

NEA Management Company sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 6,643,702 shares — an estimated $1.17M sold.

NEA Management Company first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $87.2M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • NEA Management Company reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • NEA Management Company sold 6,643,702 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1.17M.
  • NEA Management Company first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • NEA Management Company's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $87.2M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on NEA Management Company's 13F filing for Q4 2022, filed 10 Feb 2023.